Andreas Krebs

This profile gathers the share dealings of Andreas Krebs in Definium Therapeutics, Inc., where the filings describe the role as board member. In total, 5 filings cover trades dated from 1 June 2022 to 18 September 2026.

Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

Most recently, on 18 September 2026, the filings show an option exercise worth €50k in Definium Therapeutics, Inc. Typically, a trade is published a median of 3 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.